/PTGX

PTGX Stock - Protagonist Therapeutics, Inc.

Q: What is the analyst price target for PTGX?

Analyst price target information is not currently available for PTGX.

Q: What is PTGX's market cap?

Market capitalization information is not currently available for PTGX.

Healthcare|Biotechnology|NASDAQ

$81.36+1.38%

+$1.11 (+1.38%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+25.4%upside

Target: $102.03

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PTGX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.26

52W High$96.54

52W Low$33.70

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$434.43M	$60.00M	$26.58M	$27.36M	$28.63M
Gross Profit	$434.43M	$60.00M	$26.58M	$27.36M	$28.63M
Gross Margin	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income	$252.84M	$-93,652,000	$-131,373,000	$-125,845,000	$-64,516,000
Net Income	$275.19M	$-78,955,000	$-127,393,000	$-125,551,000	$-66,150,000
Net Margin	63.3%	-131.6%	-479.3%	-458.9%	-231.1%
EPS	$4.47	$-1.39	$-2.52	$-2.65	$-1.92

Company Overview

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Visit Website

Earnings History & Surprises

PTGX

Beat Rate

61%

Last 18 quarters

Avg Surprise

+274.5%

EPS vs Estimate

Beats / Misses

11/6

1 met exactly

Latest EPS

$-0.62

Q4 2025

EPS Surprise History

Q1 24

+1425.1%

$0.44vs$0.03

Q2 24

+173.9%

$3.26vs$1.19

Q3 24

0.0%

$-0.50vs$-0.50

Q4 24

+8.5%

$-0.54vs$-0.59

Q1 25

+3200.0%

$1.98vs$0.06

Q2 25

+62.0%

$-0.19vs$-0.50

Q3 25

-3.8%

$-0.55vs$-0.53

Q4 25

-5.1%

$-0.62vs$-0.59

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 4, 2026	—	—	—	—
Q1 2026	Feb 20, 2026	$-0.53	—	—	—
Q4 2025	Nov 6, 2025	$-0.59	$-0.62	-5.1%	✗ MISS
Q3 2025	Aug 6, 2025	$-0.53	$-0.55	-3.8%	✗ MISS
Q2 2025	May 6, 2025	$-0.50	$-0.19	+62.0%	✓ BEAT
Q1 2025	Feb 21, 2025	$0.06	$1.98	+3200.0%	✓ BEAT
Q4 2024	Nov 7, 2024	$-0.59	$-0.54	+8.5%	✓ BEAT
Q3 2024	Aug 6, 2024	$-0.50	$-0.50	0.0%	= MET
Q2 2024	May 7, 2024	$1.19	$3.26	+173.9%	✓ BEAT
Q1 2024	Feb 27, 2024	$0.03	$0.44	+1425.1%	✓ BEAT
Q4 2023	Nov 2, 2023	$-0.68	$-0.58	+14.7%	✓ BEAT
Q3 2023	Aug 3, 2023	$-0.65	$-0.68	-4.6%	✗ MISS
Q2 2023	May 4, 2023	$-0.69	$-0.67	+2.9%	✓ BEAT
Q1 2023	Mar 15, 2023	$-0.67	$-0.69	-3.0%	✗ MISS
Q4 2022	Nov 8, 2022	$-0.94	$-0.64	+31.9%	✓ BEAT
Q3 2022	Aug 4, 2022	$-0.99	$-0.84	+15.2%	✓ BEAT
Q2 2022	May 4, 2022	$-0.67	$-0.43	+35.8%	✓ BEAT
Q1 2022	Feb 28, 2022	$-0.79	$-0.77	+2.5%	✓ BEAT
Q4 2021	Nov 3, 2021	$-0.67	$-0.70	-4.5%	✗ MISS
Q3 2021	Aug 4, 2021	$-0.62	$-0.69	-11.3%	✗ MISS

Frequently Asked Questions about PTGX

What is PTGX's current stock price?

Protagonist Therapeutics, Inc. (PTGX) is currently trading at $81.36 per share. The stock has moved +1.38% today.

What is the analyst price target for PTGX?

The average analyst price target for PTGX is $102.00, based on 1 analyst.

What sector is Protagonist Therapeutics, Inc. in?

Protagonist Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is PTGX's market cap?

Protagonist Therapeutics, Inc. has a market capitalization of $5.09 billion, making it a mid-cap company.

Does PTGX pay dividends?

No, Protagonist Therapeutics, Inc. does not currently pay a dividend to shareholders.